Boardroom Alpha
Boardroom Alpha
MXCT · Current Report (Form 8-K) · Filed September 22, 2025

Maxcyte Inc — Current Report (Form 8-K)

Form
8-K
Filed
September 22, 2025
Period
Sep 22, 2025
Ticker
MXCT
Accession
0001104659-25-092162
Boardroom Alpha · Filing insights

MaxCyte to trim about 34% of global workforce, with approximately $2.9 million in pre-tax charges. The plan is expected to generate approximately $13.6 million in annualized savings starting in Q4 2025.

Workforce reduction
About Maxcyte Inc
Market cap
$132M
1Y TSR
−54.9%
3Y TSR
−39.7%
Board grade
C-
Sector
Healthcare
CEO
Maher Masoud
Last annual meeting: Jun 17, 2026 · View full Maxcyte Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2025

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

    

001-40674

    

52-2210438

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

9713 Key West Avenue, Suite 400

Rockville, Maryland 20850

(Address of principal executive offices, including zip code)

(301) 944-1700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading
Symbol(s)

    

Name of each exchange
on which registered

Common Stock, $0.01 par value

MXCT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.05. Costs Associated with Exit or Disposal Activities.

On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the “Plan”) as part of the Company’s ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record (“EOR”) arrangements.

In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges. The Company expects to incur these charges primarily during the third quarter of 2025 and payment of these charges are expected to occur through Q2 2026.  These charges are expected to consist of the following:

$1.8 million in severance and termination-related benefits for directly employed personnel, including cash severance and healthcare continuation;
$0.6 million in costs associated with employees engaged through EOR arrangements, including severance, benefits, and statutory notice-period wages administered in accordance with applicable labor laws in jurisdictions such as Germany, France, and the United Kingdom;
$0.4 million in wages and benefits required under the Maryland Economic Stabilization Act (commonly referred to as the “Mini-WARN Act”), which mandates 60 days’ advance notice or pay in lieu thereof for affected employees in Maryland; and
$0.1 million in other associated costs, including legal fees, consulting services, and administrative expenses related to implementing the Plan.

The actual timing and amount of these charges may differ from the Company’s current estimates due to a variety of factors, including the finalization of severance terms, jurisdiction-specific legal requirements, third-party administration of EOR-related obligations, and the pace of transition activities. The Company may also incur additional non-material charges in future periods related to the Plan.

The Company anticipates that the implementation of the Plan will be substantially completed in November 2025. The Company expects the workforce reduction to result in annualized cost savings of approximately $13.6 million, which will begin to be realized in the fourth quarter of 2025.

In addition to the Plan, the Company continues to evaluate further cost optimization other than workforce changes to align its overall cost structure and operational footprint with evolving business needs and market conditions.  

Forward-looking statements in this Current Report on Form 8-K, including those regarding the expected timing, costs, and savings related to the Plan, are subject to risks and uncertainties. These risks include, but are not limited to, the Company’s ability to complete the workforce reduction as planned and achieve the anticipated benefits related thereto. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time.

Item 7.01. Regulation FD Disclosure.

On September 22, 2025, the Company issued a press release announcing the Plan.  A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number

    

Exhibit Description

99.1

Press Release, dated September 22, 2025

104

Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MaxCyte, Inc.

Dated: September 22, 2025

By:

/s/ Douglas Swirsky

Douglas Swirsky

Chief Financial Officer

From this filing to the watchlist

Catch material events the day they file.

Boardroom Alpha's monitors flag CEO/CFO transitions, restatements, going-concern risk, auditor changes, and 8-K events the day they hit EDGAR — across 6,000+ U.S. public companies. Daily digest by watchlist, API-accessible.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Maxcyte Inc (MXCT)

Reference

Frequently asked questions

When did Maxcyte Inc file this 8-K?
Maxcyte Inc (MXCT) filed this Current Report (Form 8-K) with the SEC on September 22, 2025. The accession number assigned by EDGAR is 0001104659-25-092162.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
MaxCyte to trim about 34% of global workforce, with approximately $2.9 million in pre-tax charges. The plan is expected to generate approximately $13.6 million in annualized savings starting in Q4 2025. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What events did Boardroom Alpha flag in this filing?
BA's event-extraction layer identified this signal in the filing text: "Workforce reduction". It appears above the filing body as a labeled pill.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Maxcyte Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Maxcyte Inc has filed under CIK 1287098, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer